Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Celldex Therapeutics, Inc. - Common Stock
(NQ:
CLDX
)
31.20
+0.46 (+1.51%)
Streaming Delayed Price
Updated: 10:23 AM EDT, Mar 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Celldex Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent
↗
February 25, 2026
The company said it has enrolled patients in its late-stage program ahead of schedule.
Via
Stocktwits
Topics
Earnings
Celldex Therapeutics SVPs Engage In Heavy Transactions
↗
January 12, 2026
Multiple Senior Vice Presidents of this biotech company recently engaged in transactions that involved thousands of shares. What does this mean for the stock as it continues its long journey to regain...
Via
The Motley Fool
Topics
Regulatory Compliance
Analyst Expectations For Celldex Therapeutics's Future
↗
October 13, 2025
Via
Benzinga
Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX)
↗
October 03, 2025
CLDX stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout above the $26.20 resistance level.
Via
Chartmill
Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics
↗
February 28, 2025
Via
Benzinga
Demystifying Celldex Therapeutics: Insights From 6 Analyst Reviews
↗
January 29, 2025
Via
Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
↗
December 20, 2024
Via
Benzinga
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday?
↗
November 10, 2025
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government...
Via
Benzinga
5 Analysts Assess Celldex Therapeutics: What You Need To Know
↗
September 17, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
September 08, 2025
Via
Benzinga
Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short
↗
August 20, 2025
Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom improvement.
Via
Benzinga
What Analysts Are Saying About Celldex Therapeutics Stock
↗
August 20, 2025
Via
Benzinga
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
August 20, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
August 20, 2025
Via
Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
↗
August 20, 2025
Via
Benzinga
Why Are Celldex Shares Tumbling After Hours?
↗
August 19, 2025
The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit.
Via
Stocktwits
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
August 19, 2025
Via
Benzinga
These stocks are moving in today's after hours session
↗
August 19, 2025
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
10 Health Care Stocks Whale Activity In Today's Session
↗
August 13, 2025
Via
Benzinga
Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress
↗
August 07, 2025
Celldex Therapeutics Q2 2025 earnings: Revenue misses estimates at $730K, but EPS beats at -$0.85. Strong cash position supports pipeline, with key barzolvolimab trials progressing.
Via
Chartmill
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded
↗
June 15, 2025
Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks.
Via
Stocktwits
Crude Oil Rises 6%; US Consumer Sentiment Surges In June
↗
June 13, 2025
Via
Benzinga
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
↗
June 13, 2025
Via
Benzinga
Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics
↗
June 13, 2025
Via
Benzinga
Analyst Expectations For Celldex Therapeutics's Future
↗
April 28, 2025
Via
Benzinga
This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
↗
April 28, 2025
Via
Benzinga
7 Analysts Have This To Say About Celldex Therapeutics
↗
March 20, 2025
Via
Benzinga
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
March 20, 2025
Via
Benzinga
Baidu, Informatica And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
February 18, 2025
Via
Benzinga
Jasper Therapeutics Skin Disorder Candidate Data Fails To Cheer Investors
↗
January 08, 2025
Jasper Therapeutics reports strong briquilimab efficacy in CSU with UAS7 reductions, dose-dependent responses, and Phase 2b plans by late 2025.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
